Clinical Evaluation of E-cadherin Expression and its Regulation Mechanism in Epithelial Ovarian Cancer

Original Research

Abstract

E-cadherin plays an important role in maintaining tissue architecture. Loss of E-cadherin expression has often been associated with cancer metastasis. This study assessed the immuno-expression of E-cadherin and methylation of CDH1 and correlated them with clinical features in primary epithelial ovarian cancer. Moreover, epithelial ovarian cancer cell SKOV3 was used to explore the mechanism how the demethylating agent 5-Aza inhibited cancer metastasis. Of 80 patients with primary ovarian cancer, we found that decreased immunoexpression pattern of E-cadherin was associated with clinical stage, lymph node metastasis, and degree of differentiation. Methylation of CDH1 detected by MSP occurred frequently and was correlated with reduced expression of E-cadherin protein. 5-Aza treatment could lead to re-expression of functional E-cadherin, followed by decreased MMP-2 and MMP-9 activity and inhibition of cell invasion in SKOV3 cells. Therefore, we conclude that assessment of E-cadherin immunoreactivity or methylation of CDH1 may be a useful prognostic indicator in ovarian cancer, complementary to established prognostic factors. The mechanism underlying 5-Aza’s anti-metastasis activity is associated with restored functional expression of E-cadherin and decreased MMPs activity. Correction of aberrant DNA methylation by 5-Aza may provide a new strategy for ovarian cancer prevention and therapy.

Keywords

E-cadherin Metastasis Methylation MMPs 5-Aza Epithelial ovarian cancer 

Abbreviations

E-cadherin

epithelial cadherin

LCM

laser capture microdissection

WHO

World Health Organization

FIGO

International Federation of Gynecology and Obstetrics system

MMPs

matrix metalloproteinases

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Berkenblit A, Cannistra SA (2005) Advances in the management of epithelial ovarian cancer. J Reprod Med 50(6):426–438PubMedGoogle Scholar
  3. 3.
    Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5(5):355–366PubMedCrossRefGoogle Scholar
  4. 4.
    Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198(1):11–26PubMedGoogle Scholar
  5. 5.
    Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251(5000):1451–1455PubMedCrossRefGoogle Scholar
  6. 6.
    Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9(9):317–321PubMedCrossRefGoogle Scholar
  7. 7.
    Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM et al (2000) E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92(7):569–573PubMedCrossRefGoogle Scholar
  8. 8.
    Brinck U, Jacobs S, Neuss M, Tory K, Rath W, Kulle B et al (2004) Diffuse growth pattern affects E-cadherin expression in invasive breast cancer. Anticancer Res 24(4):2237–2242PubMedGoogle Scholar
  9. 9.
    Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP, Jr et al (2001) Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer 92(11):2786–2795PubMedCrossRefGoogle Scholar
  10. 10.
    Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108(6):2435–2447PubMedCrossRefGoogle Scholar
  11. 11.
    Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A et al (1991) E-cadherin-mediated cell–cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173–185PubMedCrossRefGoogle Scholar
  12. 12.
    Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C et al (2001) E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20(12):1525–1528PubMedCrossRefGoogle Scholar
  13. 13.
    Cleton-Jansen AM (2002) E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4(1):5–8PubMedCrossRefGoogle Scholar
  14. 14.
    Ji X, Woodard AS, Rimm DL, Fearon ER (1997) Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ 8(7):773–778PubMedGoogle Scholar
  15. 15.
    Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W (1995) Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 11(3):475–484PubMedGoogle Scholar
  16. 16.
    Yeh KT, Shih MC, Lin TH, Chen JC, Chang JY, Kao CF et al (2002) The correlation between CpG methylation on promoter and protein expression of E-cadherin in oral squamous cell carcinoma. Anticancer Res 22(6C):3971–3975PubMedGoogle Scholar
  17. 17.
    Kudo Y, Kitajima S, Ogawa I, Hiraoka M, Sargolzaei S, Keikhaee MR et al (2004) Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 10(16):5455–5463PubMedCrossRefGoogle Scholar
  18. 18.
    Kwon GY, Yoo BC, Koh KC, Cho JW, Park WS, Park CK (2005) Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J Korean Med Sci 20(2):242–247PubMedCrossRefGoogle Scholar
  19. 19.
    Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M et al (1997) The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 71(3):355–359PubMedCrossRefGoogle Scholar
  20. 20.
    Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG (2000) Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275(4):2727–2732PubMedCrossRefGoogle Scholar
  21. 21.
    Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF et al (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55(22):5195–5199PubMedGoogle Scholar
  22. 22.
    Li LC, Zhao H, Nakajima K, Oh BR, Ribeiro Filho LA, Carroll P et al (2001) Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J Urol 166(2):705–709PubMedCrossRefGoogle Scholar
  23. 23.
    Fujioka T, Takebayashi Y, Kihana T, Kusanagi Y, Hamada K, Ochi H et al (2001) Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep 8(2):249–255PubMedGoogle Scholar
  24. 24.
    Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS (2005) Biological relevance of E-cadherin–catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest 60(2):75–83PubMedCrossRefGoogle Scholar
  25. 25.
    Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD (2003) Cadherin switching in ovarian cancer progression. Int J Cancer 106(2):172–177PubMedCrossRefGoogle Scholar
  26. 26.
    Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M et al (1997) E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74(3):275–280PubMedCrossRefGoogle Scholar
  27. 27.
    Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S et al (2004) Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 35(12):1469–1476PubMedCrossRefGoogle Scholar
  28. 28.
    Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS (2004) Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 35(6):663–669PubMedCrossRefGoogle Scholar
  29. 29.
    Risinger JI, Berchuck A, Kohler MF, Boyd J (1994) Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 7(1):98–102PubMedCrossRefGoogle Scholar
  30. 30.
    Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD et al (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8(11):3324–3331PubMedGoogle Scholar
  31. 31.
    Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD et al (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11(15):5365–5369PubMedCrossRefGoogle Scholar
  32. 32.
    Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR et al (1996) Laser capture microdissection. Science 274(5289):998–1001PubMedCrossRefGoogle Scholar
  33. 33.
    Scully R (ed) (1999) Histological typing of ovarian tumors. WHO international classification of tumours, 2nd edn. Springer, BerlinGoogle Scholar
  34. 34.
    Pecorelli S, Benedet JL, Creasman WT, Shepherd JH (1999) FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 65(3):243–249PubMedCrossRefGoogle Scholar
  35. 35.
    Hensley ML (2002) Epithelial ovarian cancer. Curr Treat Options Oncol 3(2):131–141PubMedCrossRefGoogle Scholar
  36. 36.
    Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93(18):9821–9826PubMedCrossRefGoogle Scholar
  37. 37.
    Sheng S (2001) The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20(3–4):287–296PubMedCrossRefGoogle Scholar
  38. 38.
    Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB et al (1998) Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma. Cancer Res 58(10):2063–2066PubMedGoogle Scholar
  39. 39.
    Wong AS, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PC et al (1999) Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Int J Cancer 81(2):180–188PubMedCrossRefGoogle Scholar
  40. 40.
    Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J et al (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59(5):1090–1095PubMedGoogle Scholar
  41. 41.
    Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P et al (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28(8):922–928PubMedCrossRefGoogle Scholar
  42. 42.
    Hoffman AG, Burghardt RC, Tilley R, Auersperg N (1993) An in vitro model of ovarian epithelial carcinogenesis: changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer 54(5):828–838PubMedCrossRefGoogle Scholar
  43. 43.
    Veatch AL, Carson LF, Ramakrishnan S (1994) Differential expression of the cell–cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 58(3):393–399PubMedCrossRefGoogle Scholar
  44. 44.
    Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S et al (1999) E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96(11):6249–6254PubMedCrossRefGoogle Scholar
  45. 45.
    Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16(4):168–174PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynecology, Xijing HospitalFourth military Medical UniversityXi’an, ShaanxiChina
  2. 2.Department of Obstetrics and Gynecology, Affiliated Hospital of Yan’an Medical CollegeYan’an UniversityYan’anChina

Personalised recommendations